Bupropion (previously known as amfebutamone; Wellbutrin, Zyban) is an atypical antidepressant that acts as a norepinephrine and dopamine reuptake inhibitor, and nicotinic antagonist. Bupropion belongs to the chemical class of aminoketones and is similar in structure to the stimulant cathinone, to the anorectic diethylpropion, and to phenethylamines in general. Initially researched and marketed as an antidepressant, bupropion was subsequently found to be effective as a smoking cessation aid.
At the beginning of each new year, many people make resolutions to improve their health; they may aim to lose weight, stop smoking, exercise more, remember to take prescriptions as directed.
The results of a study conducted by Dr. Anick Bérard, Professor and Fonds de recherche du Québec - Santé Research Chair on Medications and Pregnancy, at the University of Montreal's Faculty of Pharmacy and the Ste-Justine University Hospital demonstrate that the use of nicotine patches or the drug Zyban has positive effects for the unborn child and allows pregnant women to stop smoking during and after pregnancy.
A new study led by Assistant Medical Professor Philip Smith of The City College of New York's Sophie Davis Biomedical Education/CUNY School of Medicine, and conducted in collaboration with researchers at Yale University and Yeshiva University, found important differences between women and men in their ability to quit smoking when taking medications commonly prescribed to help smokers quit.
Compared to the nicotine patch and a placebo, the smoking cessation aids varenicline (marketed as Chantix in the U.S.) and bupropion (Zyban) do not show a significant increase in neuropsychiatric adverse events, reports an international team of researchers in a study published online April 22 in the journal The Lancet.
The most effective prescription drug used to quit smoking initially helps women more than men, according to a Yale School of Medicine study. The study, published Oct. 7 by the journal Nicotine and Tobacco Research, found that varenicline, marketed as Chantix, was more effective earlier in women, and equally effective in women and men after one year.
The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according to a study led by researchers at University of California, San Diego School of Medicine.
The Arentz Law Group is currently investigating cases of birth defects caused by the stop-smoking drug Zyban. Women who have taken Zyban while pregnant, and given birth to a child born with a birth defect, are encouraged to contact the law firm immediately for a free legal consultation.
Smokers may be more likely to successfully quit their habit if simple adjustments were made to how an existing anti-smoking medication is prescribed, according to a new study by a University at Buffalo research team.
Combining two smoking cessation therapies is more effective than using just one for male and highly nicotine-dependent smokers who weren't initially helped by the nicotine patch, according to researchers at Duke Medicine.
A study to assess whether patients prescribed smoking cessation drugs are at an increased risk of suicide, self-harm and treated depression compared with users of nicotine replacement therapy has found no evidence of an increased risk.
A new editorial released this week offers clarity and structure on confusing drug and alcohol addiction terminology for prescribers, users and regulators. "Through a glass darkly: can we improve clarity about mechanism and aims of medications in drug and alcohol treatments?" is published in the Journal of Psychopharmacology, the official journal of the British Association for Psychopharmacology, published by SAGE.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, announced today that enrollment of its X-22 Phase II-B clinical trial has been successfully completed; 234 smokers have been randomized in the double-blind, active-controlled, multi-center smoking cessation study.
With rise obesity around the world there should have been a number of drugs to combat it. The reality is different. There are no safe and effective drugs in the market at present.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that its wholly-owned subsidiary, 22nd Century Limited, LLC, enrolled the first patients in its Phase II-B clinical trial for X-22, a prescription smoking cessation aid in development.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction products, today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) Application to conduct a Phase II-B clinical trial using X-22, a prescription smoking cessation aid in development.
22nd Century Group, Inc., a company focused on smoking cessation and tobacco harm reduction, announced today that 22nd Century Limited, LLC submitted an Investigational New Drug Application (IND) to the U.S. Food & Drug Administration (FDA) for X-22, a prescription smoking cessation aid in development.
22nd Century Limited, LLC, a company focused on smoking cessation and tobacco harm reduction products, announced that it has been awarded $244,000 in grant funding as part of the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.
Researchers may have pinpointed a reason many smokers struggle to quit. According to new research published in the journal Addiction, smokers with a history of anxiety disorders are less likely to quit smoking. The study, conducted by the University of Wisconsin Center for Tobacco Research and Intervention (UW-CTRI), offered free coaching and medications to smokers in Madison and Milwaukee.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Bupropion Hydrochloride Extended-release Tablets USP, 150 mg, the generic version of GlaxoSmithKline's smoking cessation aid, Zyban.
Recently published research has shown that some breast cancer patients taking tamoxifen may not be getting the full benefit of their treatment because they have also been taking selective serotonin reuptake inhibitors, prescribed drugs that inhibit the effect of an important enzyme.